PARP1 and breast cancer: miR-361-3p expression is associated with reduced BC patient survival and its inhibitors may represent effective therapeutics for BC treatment, both in endocrine-responsive and -resistant disease, particularly since miR-361-3p inhibitor showed synergy with PARP inhibition.